Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Introducing Revela Hair Revival Serum, A Breakthrough Formula for Hair Thinning and Hair Loss From a Maverick Beauty and Wellness Brand

Using a combination of cutting-edge synthetic biology, machine learning and advanced biological models to discover new ingredients in the biotech arena, the team behind Revela's Hair Revival Serum is applying these same techniques to address ingredient discovery in the beauty and wellness space, starting with female hair loss.


News provided by

Revela

Feb 04, 2022, 08:00 ET

Share this article

Share toX

Share this article

Share toX


NEW YORK, Feb. 4, 2022 /PRNewswire-PRWeb/ -- Most beauty products use formulas that consist of different combinations of the same, pre-existing ingredients – just formulated in different ways and without any improvements in performance. There are still less than 33,000 naturally-occurring ingredients available for use in OTC beauty products, many with limited efficacy and/or side effects, while there are over three billion safe and synthesizable chemical molecules available for discovery and application. Revela was founded on the belief that new, more effective ingredients have yet to be discovered and that the next generation of beauty and wellness products are just waiting to be developed.

Revela's foundational ingredient discovery process is an elegant, innovative and evolved approach that is set to disrupt the traditional model of beauty and wellness product development:

"The reason we can provide products with this level of efficacy is because this technology didn’t exist before. We work and re-work until our ingredients provide an answer to the issue at hand. No compromising," says David.

Post this

1. Using proprietary biosensors and assays to probe biological models.
2. This data is then used to train AI models to predict new, safe synthetic compounds that enhance
human health.
3. These compounds are then validated in sophisticated biological models (e.g., organoids, ex-vivo) to
ensure that they are safe and efficacious. This research method does not use any fetal or human
embryonic stem cells, is cruelty-free and never tested on animals.

Founded by an impressive, young entrepreneurial team, the "brain trust" behind Revela notably
includes Evan Zhao, a synthetic biologist and chemical engineer with a BS from Caltech and an MA/PhD from Princeton, David Zhang, an immunologist and bioengineer with a Harvard PhD, Avinash Boppana, with a BS from Princeton in Statistics and Machine Learning and pursuing a PhD at MIT in computer science and Evelyn Chen, with an MS is Biomedical Engineering from Columbia and a beauty industry pedigree as the founder of the breakthrough acne brand NERD skincare.

"At Revela, we begin our process by challenging the status quo to see where you can improve. Using
AI, we lead the discovery of completely new ingredients to offer products with real, targeted results.
Our technology allows us to scan the library of 3 billion molecules and create a shortlist of ingredients
with the highest potential of being the perfect solution with no trial and error involved," says Evan.

"The reason we can provide products with this level of efficacy is because this technology didn't exist
before. We work and re-work until our ingredients provide an answer to the issue at hand. No compromising," says David.

Revela's Hair Revival Serum: Hair loss and hair thinning is a universal issue, and an especially
challenging one for women with no consistent or effective solutions available. There are currently only
two main ingredients to treat hair loss with well-studied results, both of which have significant downsides: Minoxidil is inconsistent and takes months to see mediocre results and Finasteride is a steroid-like medication, which while effective for male pattern baldness, has major side effects, including impotence issues in men due to its manipulation of testosterone. More importantly, it does not work for women.

The breakthrough ingredient in Revela's Hair Revival Serum is ProCelinyl™, a molecule composed of components from natural ingredients commonly found in mushrooms and mustard plants, but is a completely new chemical entity, boosting daily hair follicle growth by 50%and supporting hair and
follicle health more consistently than any other ingredient on the market today. In a six-week clinical
trial 97% of women saw improvements in their hair. In addition to ProCelinyl ™, Revela's Hair Revival
Serum includes Aloe Vera, Caffeine, and Vitamin E to support overall hair and scalp with zero toxins,
hormones or harmful chemicals in the formulation and is suitable for color-treated, keratin-treated,
chemically-treated or relaxed hair.

Revela's Safety Protocol: Revela was founded on the belief that better results should not compromise
on heath or safety. Once validated, each potential ingredient is then vigorously tested to guarantee
both efficacy and safety. Unlike other cosmetic brands that spend millions of dollars to merely monitor
changes in regulations of existing raw or manufactured ingredients, Revela set out to raise the bar for
cosmetic safety and testing with a pipeline modeled after advanced therapeutics development:

  • All active ingredients are tested to ensure they are safe to use, with no side effects.
  • Revela performs a series of tests of increasing complexity to make sure that each ingredient only

targets the area of focus; such as hair follicles, in the case of the Hair Revival Serum.

  • The best ingredients are tested for molecular and cellular toxicity and any potential skin irritation.
  • Any ingredients that show any form of toxicity or irritation, even in the smallest amounts, are

immediately eliminated.

  • Revela uses advanced computational tools to benchmark their ingredients against current standards,

taking advantage of years previous scientific research.

  • The patent-pending, active ingredient in Revela's new Hair Revival Serum has passed every test

performed, confirming its absolute safety.

  • Everything is tested in extensive clinical safety tests.

Revela Hair Revival Serum: US retail, $98 30ml (or $78 monthly subscription)

Revela Eyebrow Serum: US retail. $88 5ml (4-6 month supply).

  • A thicker serum that stays on the skin underneath your eyebrow, promoting overall follicle health using our patent-pending ingredient, ProCelinyl™. See results in as little as 2-3 weeks of daily use. Each tube comes with enough serum for 4 months of daily use.

For additional information, images or product, please contact: [email protected] / [email protected]

Media Contact

Matthew Snyder, MBA Partners, 1 6468894551, [email protected]

SOURCE Revela

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.